Overall Survival Benefit Up for Pyrotinib + Capecitabine in HER2-Positive Breast Cancer

THURSDAY, Nov. 16, 2023 -- For patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, pyrotinib plus capecitabine offers an overall survival benefit, according to a study presented at the Advanced Breast...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news